Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference
Rhea-AI Summary
Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage company focused on gene therapy for ocular diseases, has announced its participation in the 2025 RBC Capital Markets Ophthalmology Virtual Conference. The company will engage in a fireside chat scheduled for Thursday, April 3 at 10:45 a.m. ET.
Interested parties can access the webcast through the Events and Presentations section of Adverum's website in the Investors area. The recording will remain available for a minimum of 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ADVM declined 12.36%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will participate in a fireside chat at the 2025 RBC Capital Markets Ophthalmology Virtual Conference on Thursday, April 3 at 10:45 a.m. ET.
The webcast of the fireside chat may be accessed under Events and Presentations in the Investors section of Adverum’s website. A replay of the webcast will be available on the website for at least 30 days following the event.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.
Inquiries:
Adverum Investor Relations
Email: ir@adverum.com
FAQ
When is Adverum Biotechnologies (ADVM) presenting at the RBC Capital Markets Conference 2025?
How can investors access ADVM's presentation at the RBC Ophthalmology Conference?
How long will ADVM's RBC Conference presentation replay be available?
What is the focus of Adverum Biotechnologies' (ADVM) research and development?
